drugset / Trial / NCT01187446

Low-dose (12 Gy) TSEBT+Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides

NCT01187446

Phase 1/2 Terminated 28 enrolled Stanford University
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine if vorinostat combined with low-dose total skin electron beam therapy (TSEBT) offers superior clinical benefit (efficacy \& safety) over low-dose TSEBT alone in participants with mycosis fungoides (MF) Treatment in this study is TSEBT +/- vorinostat, with participants stratified by MF stage.

Timeline

Start
2010-12
Primary completion
2013-08
Completion
2014-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Vorinostat Small molecule 400 mg